Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Henggliejin (Hengagliflozin) for serum uric acid reduction in type 2 diabetes
ChiCTR2400091899Phase 4Not yet recruiting
- Sponsor
- Zhanjiang Central People's Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of henagliflozin in type 2 diabetes mellitus (T2DM) and hyperuricemia, sponsored by Zhanjiang Central People's Hospital. Primary endpoint: Serum uric acid. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hyperuricemia
Beyond the preview
Go deeper on ChiCTR2400091899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091899.